BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100
Ad hoc announcement pursuant to Art. 53 LR
- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC).